Alyson Haslam1, Jennifer Gill2, Tyler Crain3, Diana Herrera-Perez4, Emerson Y Chen4, Talal Hilal5, Myung S Kim4, Vinay Prasad6. 1. Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. 2. Providence Health & Services, Portland, OR, USA. 3. Department of Analytics, Northwest Permanente, Portland, OR, USA. 4. Oregon Health & Science University, Portland, OR, USA. 5. University of Mississippi Medical Center, Jackson, MS, USA. 6. Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. vinayak.prasad@ucsf.edu.
Abstract
BACKGROUND: Identifying ineffective practices that have been used in oncology is important in reducing wasted resources and harm. We sought to examine the prevalence of practices that are being used but have been shown in RCTs to be ineffective (medical reversals) in published oncology studies. METHODS: We cross-sectionally analyzed studies published in three high-impact oncology medical journals (2009-2018). We abstracted data relating to the frequency and characterization of medical reversals. RESULTS: Of the 64 oncology reversals, medications (44%) represented the most common intervention type (39% were targeted). Fourteen (22%) were funded by pharmaceutical/industry only and 56% were funded by an organization other than pharmaceutical/industry. The median number of years that the practice had been in use prior to the reversal study was 9 years (range 1-50 years). CONCLUSION: Here we show that oncology reversals most often involve the administration of medications, have been practiced for years, and are often identified through studies funded by non-industry organizations.
BACKGROUND: Identifying ineffective practices that have been used in oncology is important in reducing wasted resources and harm. We sought to examine the prevalence of practices that are being used but have been shown in RCTs to be ineffective (medical reversals) in published oncology studies. METHODS: We cross-sectionally analyzed studies published in three high-impact oncology medical journals (2009-2018). We abstracted data relating to the frequency and characterization of medical reversals. RESULTS: Of the 64 oncology reversals, medications (44%) represented the most common intervention type (39% were targeted). Fourteen (22%) were funded by pharmaceutical/industry only and 56% were funded by an organization other than pharmaceutical/industry. The median number of years that the practice had been in use prior to the reversal study was 9 years (range 1-50 years). CONCLUSION: Here we show that oncology reversals most often involve the administration of medications, have been practiced for years, and are often identified through studies funded by non-industry organizations.
Authors: Guy A van Hazel; Volker Heinemann; Navesh K Sharma; Michael P N Findlay; Jens Ricke; Marc Peeters; David Perez; Bridget A Robinson; Andrew H Strickland; Tom Ferguson; Javier Rodríguez; Hendrik Kröning; Ido Wolf; Vinod Ganju; Euan Walpole; Eveline Boucher; Thomas Tichler; Einat Shacham-Shmueli; Alex Powell; Paul Eliadis; Richard Isaacs; David Price; Fred Moeslein; Julien Taieb; Geoff Bower; Val Gebski; Mark Van Buskirk; David N Cade; Kenneth Thurston; Peter Gibbs Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Suzanne K Chambers; Stefano Occhipinti; Elizabeth Foley; Samantha Clutton; Melissa Legg; Martin Berry; Martin R Stockler; Mark Frydenberg; Robert A Gardiner; Stephen J Lepore; Ian D Davis; David P Smith Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Kim A H Nicolaije; Nicole P M Ezendam; M Caroline Vos; Johanna M A Pijnenborg; Dorry Boll; Erik A Boss; Ralph H M Hermans; Karin C M Engelhart; Joke E Haartsen; Brenda M Pijlman; Ingrid E A M van Loon-Baelemans; Helena J M M Mertens; Willem E Nolting; Johannes J van Beek; Jan A Roukema; Wobbe P Zijlstra; Roy F P M Kruitwagen; Lonneke V van de Poll-Franse Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Diana Herrera-Perez; Alyson Haslam; Tyler Crain; Jennifer Gill; Catherine Livingston; Victoria Kaestner; Michael Hayes; Dan Morgan; Adam S Cifu; Vinay Prasad Journal: Elife Date: 2019-06-11 Impact factor: 8.140
Authors: Marie Fallon; Peter J Hoskin; Lesley A Colvin; Susan M Fleetwood-Walker; Douglas Adamson; Anthony Byrne; Gordon D Murray; Barry J A Laird Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544